Rhumbline Advisers Makes New $300,000 Investment in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Rhumbline Advisers acquired a new position in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) in the second quarter, HoldingsChannel.com reports. The firm acquired 13,231 shares of the company’s stock, valued at approximately $300,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new stake in shares of Jasper Therapeutics during the first quarter worth $306,000. Concurrent Investment Advisors LLC acquired a new stake in shares of Jasper Therapeutics during the first quarter worth $599,000. Bank of New York Mellon Corp acquired a new stake in shares of Jasper Therapeutics during the second quarter worth $740,000. Russell Investments Group Ltd. acquired a new stake in shares of Jasper Therapeutics during the first quarter worth $2,343,000. Finally, Kingdon Capital Management L.L.C. lifted its holdings in shares of Jasper Therapeutics by 16.4% during the fourth quarter. Kingdon Capital Management L.L.C. now owns 3,540,000 shares of the company’s stock worth $2,793,000 after buying an additional 500,000 shares in the last quarter. 79.85% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on JSPR shares. Evercore ISI reissued an “outperform” rating and set a $65.00 target price on shares of Jasper Therapeutics in a report on Monday, August 26th. Cantor Fitzgerald reissued an “overweight” rating on shares of Jasper Therapeutics in a report on Monday, September 9th. Stifel Nicolaus assumed coverage on Jasper Therapeutics in a research note on Thursday, June 27th. They issued a “buy” rating and a $86.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and issued a $65.00 price target on shares of Jasper Therapeutics in a research note on Tuesday, August 13th. Finally, BTIG Research assumed coverage on Jasper Therapeutics in a research note on Monday, July 8th. They issued a “buy” rating and a $90.00 price target for the company. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Jasper Therapeutics presently has a consensus rating of “Buy” and an average target price of $73.00.

Jasper Therapeutics Trading Down 0.1 %

Shares of NASDAQ JSPR opened at $18.83 on Friday. The company has a market cap of $283.66 million, a price-to-earnings ratio of -3.34 and a beta of 2.22. Jasper Therapeutics, Inc. has a 12 month low of $4.00 and a 12 month high of $31.01. The stock has a 50-day moving average price of $19.66 and a two-hundred day moving average price of $22.50.

Jasper Therapeutics (NASDAQ:JSPR) last issued its earnings results on Tuesday, August 13th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($1.09) by $0.12. On average, sell-side analysts predict that Jasper Therapeutics, Inc. will post -4.16 earnings per share for the current year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.